View as cardsView as table92 Projects

Bacterial siderophores for accelerated mineral weathering and carbon sequestration in seawater

Fiscal Year Awarded:

2026

Principal Investigator:

Pamela Silver

Brain specific modulation of thyroid hormone levels

Fiscal Year Awarded:

2026

Principal Investigator:

Bernardo Sabatini

Development of a novel therapeutic to accelerate epithelial repair following viral respiratory infection

Fiscal Year Awarded:

2026

Principal Investigator:

Ruth Franklin

Enhanced dual-AAV gene delivery to treat hereditary deafness

Fiscal Year Awarded:

2026

Principal Investigator:

David Corey

Enhancing regulatory T cell function for adoptive CAR Treg therapy to treat autoimmune disease

Fiscal Year Awarded:

2026

Principal Investigator:

Arlene Sharpe

Melanocortin 1 receptor agonists for preventing skin cancer

Fiscal Year Awarded:

2026

Principal Investigator:

Andrew Kruse

Non-invasive theranostics for endometriosis

Fiscal Year Awarded:

2026

Principal Investigator:

Ulrich von Andrian

Potassium channel enhancers to treat pain and epilepsy

Fiscal Year Awarded:

2026

Principal Investigator:

Bruce Bean

Targeting a protein to promote remyelination

Fiscal Year Awarded:

2026

Principal Investigator:

Lee Rubin

Targeting Ecdysone signaling for control of disease vector and other insects

Fiscal Year Awarded:

2026

Principal Investigator:

Norbert Perrimon

Towards the development of improved insect repellents

Fiscal Year Awarded:

2026

Principal Investigator:

Josefina del Marmol

V8 protease to treat S. aureus infection and atopic dermatitis

Fiscal Year Awarded:

2026

Principal Investigator:

Isaac Chiu

Developing a biomarker of homologous recombination deficiency for enhanced PARP inhibitor efficacy across cancers

Fiscal Year Awarded:

2025

Principal Investigator:

Peter Park

Developing a synthetic biology platform for pharmaceutical biomanufacturing

Fiscal Year Awarded:

2025

Principal Investigator:

Pamela Silver

Development of allosteric activators for immunotherapy

Fiscal Year Awarded:

2025

Principal Investigator:

Stephen Blacklow

Development of small molecule inhibitors of a gut bacterial metabolic toxin

Fiscal Year Awarded:

2025

Principal Investigator:

Sloan Devlin

In vivo gene editing to treat inherited Collagen VI-related myopathies

Fiscal Year Awarded:

2025

Principal Investigator:

Amy Wagers

In vivo strategy to induce tolerance to therapeutic proteins and autoantigens

Fiscal Year Awarded:

2025

Principal Investigator:

Amy Wagers

Investigating the mode of action of a highly selective insecticide and suitability for Anopheles management

Fiscal Year Awarded:

2025

Principal Investigator:

Norbert Perrimon

Oral pan-coronavirus anti-viral

Fiscal Year Awarded:

2025

Principal Investigator:

Timothy Mitchison